| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Biologics | Respiratory System | ||
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Biologics | Respiratory System | ||
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Biologics | Respiratory System |
Recent Updates
Recently added Catalysts
Connect Biopharma Holdings Limited$2.66
+0.41 (+18.5%)
D 28Pipeline Score Richly Valued Pharma · Commercial
Market Cap
147.97 M
EPS
-1.15
P/E Ratio
-
Value Trade
1.05 M
SEC Financials
Q1 2026Dilution Risk
Revenue
169.00 K
R&D Expenses
15.03 M
Operating CF
-16.00 M
Total Assets
60.07 M
Total Liabilities
17.44 M
Equity
42.62 M
D/E Ratio
12,345
-2.89 %
Week
-11.32 %
1 Month
-18.12 %
3 Month
-21.14 %
6 Month
-85.15 %
5 Year
-87.98 %
All Time
Cash Data
Cash Position
46.03 M
Monthly Burn
5.33 M
Runway
6.9 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
2.46 M
52 Week Range
0.73 - 3.82
% held by Insiders
75.49 %
% held by Institutions
20.25 %
Enterprise Value
102.62 M
Total Shares
56.52 M
Short %
1.88 %
Float Shares
56.52 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Connect Biopharma Holdings Limited
224Total events
5Upcoming
70Tier-1 (high impact)
2021 – 2027Coverage
Upcoming catalysts 5
Sep 2026
T1Topline Readout
Topline data from Phase 2 Seabreeze STAT COPD study expected soon after September 2026
Event history 219
Jun 17, 2026
▲Enrollment CompleterademikibartTrial
Completed enrollment in Phase 2 Seabreeze STAT Asthma study
acute exacerbations in asthma with type 2 inflammationsource ↗
Jun 2026
▲Enrollment CompleterademikibartTrial
Expected completion of enrollment in Phase 2 Seabreeze STAT COPD study this month
acute exacerbations in COPD with type 2 inflammationsource ↗
May 19, 2026
◆Oral PresentationPresentation
Fireside chat at H.C. Wainwright 4th Annual BioConnect Investor Conference
Apr 23, 2026
▲Interim AnalysisrademikibartTrial
DMC completed pre-specified interim analysis of efficacy with no recommendation for change in sample size
acute exacerbations of asthmasource ↗
Q2 2026
◆Topline ReadoutrademikibartClinical Data
Topline data expected from Phase 2 Seabreeze STAT studies
acute exacerbations in asthma and COPDsource ↗
Apr 2026
▲Interim AnalysisrademikibartTrial
Independent DMC review of pre-specified interim analysis with no recommendation for change in sample size and no safety concerns
acute exacerbations of asthma and COPDsource ↗
Mar 31, 2026
▲Topline ReadoutrademikibartClinical Data
Positive topline data from Phase 1 IV study of rademikibart in asthma or COPD
asthma or COPDsource ↗
Mar 31, 2026
◆Oral PresentationrademikibartPresentation
Phase 3 rademikibart AD results presented in late-breaking session at AAD
moderate-to-severe atopic dermatitissource ↗
Mar 30, 2026
▲Full ResultsrademikibartClinical Data
Phase 3 RADIANT-AD 52-week results announced
moderate-to-severe atopic dermatitissource ↗
Drug Pipeline Intelligence
D28
Pipeline Score $4M
Pipeline ValueRichly Valued
Valuation Signal2
Drugs Scored0.0x
rNPV / MCap Top 31%
Micro Cap (rank 626 of 906)
Percentile RankConnect Biopharma Holdings Limited faces pipeline headwinds (28/100), with $129M risk-adjusted pipeline value, led by CBP-307 in Autoimmune Diseases (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CBP-307 Small molecule | Autoimmune Diseases | Phase 1 | NCT04818229 | 10% | $94M | COMPLETED | 112 | - | - | Mar 30, 2022 | - | Nov 4, 2024 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
rademikibart | asthma or COPD | Phase 1 | 2026-05-12 | a single IV administration of rademikibart rapidly improved lung function as early as 15 minutes post-dosing; clinically meaningful improvements in forced expiratory volume in one second (FEV1) generally maintained for up to four weeks Read More | Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update Read More | |
rademikibart | asthma or COPD | Phase 1 | 2026-05-12 | a single IV administration of rademikibart rapidly improved lung function as early as 15 minutes post-dosing; clinically meaningful improvements in forced expiratory volume in one second (FEV1) generally maintained for up to four weeks Read More | Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update Read More | |
rademikibart | asthma or COPD | Phase 1 | 2026-05-12 | a single IV administration of rademikibart rapidly improved lung function as early as 15 minutes post-dosing; clinically meaningful improvements in forced expiratory volume in one second (FEV1) generally maintained for up to four weeks Read More | Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CNTB
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CNTB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CNTBConnect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
Connect Biopharma has completed enrollment in its Phase 2 Seabreeze STAT Asthma study, which evaluates rademikibart for treating acute asthma exacerbations. The company expects to report topline data in early September 2026 and aims to finalize enrollment in the Seabreeze STAT COPD study soon. With a solid financial foundation, Connect is preparing to engage with the FDA regarding a Phase 3 program.
Read more →CNTB▼ -8.6%on this news
Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
Connect Biopharma Holdings Limited will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026. The company is focused on developing rademikibart, a next-generation antibody for treating asthma and COPD. An archived replay of the presentation will be available for 90 days post-conference.
Read more →CNTB▲ +14.5%on this newsshared move
Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update
Connect Biopharma has reported its first-quarter financial results for 2026, indicating a net loss of $19.4 million. The company is progressing in its Phase 2 Seabreeze STAT studies for asthma and COPD, expecting topline data by mid-2026. A recent $20.2 million financing bolsters its operations, allowing for ongoing development of rademikibart, which has shown promising preliminary results. Despite financial challenges, management remains optimistic about the product's potential in the market.
Read more →CNTBConnect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis - Expect to report topline data from both studies mid-2026
Connect Biopharma announced that enrollment in its ongoing Phase 2 Seabreeze STAT studies for rademikibart will proceed as planned. The independent Data Monitoring Committee confirmed the efficacy analysis without recommending any changes to sample size. Rademikibart continues to show positive tolerability among patients, and topline results are expected to be reported by mid-2026. The company is also aligning with the FDA for future Phase 3 program development.
Read more →CNTBConnect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update
Connect Biopharma reported its 2025 financial results, highlighting significant progress in its lead drug candidate, rademikibart. The company released positive data from a Phase 1 study and is currently recruiting for Phase 2 studies aimed at asthma and COPD. Additionally, a $20.2 million equity financing was secured to support ongoing operations.
Read more →CNTB▼ -15.9%on this newsshared move
Connect Biopharma Announces $20.2 Million Private Placement Financing
Connect Biopharma has announced a private placement financing of $20.2 million, which will extend its cash runway into the second half of 2027. The financing involves the sale of 6,130,000 shares at $3.25 each, led by its largest investor, Panacea Venture. The funds will support research and development of clinical-stage products and general corporate purposes.
Read more →CNTB▼ -15.9%on this newsshared move
Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study
Connect Biopharma announced positive results from a Phase 3 study of rademikibart for moderate-to-severe atopic dermatitis. The study demonstrated significant efficacy with ~90% of patients achieving near-maximal responses. Safety was comparable to placebo, with low rates of conjunctivitis. The findings were presented at the 2026 American Academy of Dermatology Annual Meeting.
Read more →CNTB▼ -15.9%on this newsshared move
Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD
Connect Biopharma announced positive topline results from its Phase 1 study of intravenous rademikibart, showing rapid and sustained improvements in lung function for asthma and COPD patients. The study demonstrated significant FEV1 improvements as early as 15 minutes post-dosing, with effects maintained through Day 29. The company plans to advance to Phase 2 studies and engage with the FDA for a Phase 3 program.
Read more →CNTBConnect Biopharma to Present at the Leerink Partners Global Healthcare Conference
Connect Biopharma Holdings Limited will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on March 10, 2026. The event will be accessible via a live webcast, with an archived replay available for 90 days. The company is focused on developing rademikibart, a treatment for asthma and COPD, and has a licensing agreement with Simcere Pharmaceutical for the drug in Greater China.
Read more →CNTBConnect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Connect Biopharma Holdings Limited will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. The company focuses on innovative treatments for inflammatory diseases, particularly asthma and COPD. They are advancing their therapy, rademikibart, which targets IL-4Rα and is currently undergoing global clinical trials. Connect has also established a collaboration with Simcere Pharmaceutical for the commercialization of rademikibart in Greater China.
Read more →CNTBConnect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026
Connect Biopharma has revealed new data supporting the unique mechanism of action for its drug rademikibart, highlighting its potential for rapid airway improvement. The company is currently recruiting patients for both Phase 1b and Phase 2 clinical studies targeting asthma and COPD, with topline results expected through mid-2026. Financially, Connect Biopharma has a solid cash position, likely sustaining operations through key clinical developments into 2027. Additional studies provide evidence of improved efficacy compared to existing treatments, suggesting rademikibart may effectively address significant unmet medical needs.
Read more →CNTBConnect Biopharma to Present at the 8th Annual Evercore Healthcare Conference
Connect Biopharma Holdings Limited has announced its participation in the 8th Annual Evercore Healthcare Conference, scheduled for December 2nd, 2025. The company will engage in a fireside chat about its clinical-stage products, including rademikibart, designed to treat asthma and COPD. Connect is currently conducting global clinical studies and has licensed its product for distribution in Greater China. This involvement highlights the company's commitment to advancing treatment options in inflammatory diseases.
Read more →CNTB▲ +5.9%on this news· ran to +64% by day 3
Connect Biopharma Reports Third Quarter 2025 Financial Results and Provides Business Update
Connect Biopharma reported its third quarter 2025 financial results, highlighting ongoing recruitment for Phase 2 Seabreeze STAT studies targeting acute exacerbations in asthma and COPD. The company announced that the New Drug Application for rademikibart, aimed at treating atopic dermatitis, was accepted by China's NMPA. Additionally, positive data was presented at ERS 2025 regarding rademikibart's efficacy.
Read more →CNTB▼ -16.6%on this news
Connect Biopharma Presents Data Supporting Rademikibart at the European Respiratory Society Congress 2025
Connect Biopharma presented promising data for rademikibart at the ERS Congress 2025, highlighting its efficacy in improving lung function and asthma control, particularly in patients with elevated inflammatory markers. The findings support ongoing Phase 2 studies for asthma and COPD, with topline data anticipated in early 2026. The company aims to establish rademikibart as a leading treatment option in these areas.
Read more →CNTB▼ -10.6%on this news
Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025
Connect Biopharma announced two poster presentations at the European Respiratory Society Congress 2025, focusing on their product rademikibart for asthma treatment. The presentations will take place on September 29, 2025, and will cover the impact of eosinophils on treatment response. Rademikibart targets interleukin-4 receptor alpha, aiming to block inflammatory pathways associated with asthma.
Read more →CNTB▼ -5.7%on this newsshared move
Connect Biopharma Completes Termination of its American Depositary Receipt Program and Directly Lists its Ordinary Shares on Nasdaq
Connect Biopharma has terminated its American Depositary Receipt program and directly listed its ordinary shares on Nasdaq. This transition is aimed at increasing visibility among U.S. investors and enhancing shareholder value. The company continues to advance its clinical studies for rademikibart, a monoclonal antibody targeting inflammatory diseases such as asthma and COPD.
Read more →CNTBConnect Biopharma to Present at Two Upcoming Investor Conferences in September
Connect Biopharma Holdings Limited will participate in two investor conferences in September 2025. The Cantor Global Healthcare Conference is scheduled for September 3rd, followed by the H.C. Wainwright 27th Annual Global Investment Conference on September 8th. The company is focused on its clinical-stage product, rademikibart, aimed at treating inflammatory diseases.
Read more →CNTB▼ -8.9%on this news· ran to -23% by day 3
Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide
Connect Biopharma has partnered with the Jovante Woods Foundation to expand asthma education across the U.S. This initiative, led by former NFL player Ickey Woods, aims to raise awareness about the dangers of acute asthma attacks and promote new treatments. The collaboration includes community events and a social media campaign to educate families on asthma management.
Read more →CNTBConnect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update
Connect Biopharma reported its financial results for the second quarter of 2025, highlighting progress in its clinical development and business strategy. The company initiated Phase 2 studies for rademikibart, targeting asthma and COPD, and presented positive data at major medical conferences. A new drug application for rademikibart in China has been submitted, and the company plans to terminate its ADR program to enhance institutional visibility. Despite a reported net loss, Connect Biopharma is optimistic about its future growth prospects.
Read more →CNTB▲ +19%on this news
Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors
Connect Biopharma has expanded its Board of Directors by appointing Jim Schoeneck, an industry veteran with over 40 years of experience in drug development and commercialization. His expertise is expected to enhance the company's efforts in advancing rademikibart, a treatment for asthma and COPD, as they move towards Phase 2 clinical studies. The company anticipates clinical data in the first half of 2026.
Read more →CNTB▲ +16.3%on this news· ran to +38% by day 1shared move
Connect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on Nasdaq
Connect Biopharma Holdings Limited plans to terminate its American Depositary Receipt (ADR) program and directly list its ordinary shares on Nasdaq by September 2, 2025. This decision aims to facilitate institutional visibility and reduce depositary fees for shareholders. Concurrently, the company is advancing its Phase 2 clinical development program for rademikibart, an antibody targeting IL-4Rα for asthma and COPD treatment. The transition to a direct listing is anticipated to strengthen its investor base and support long-term shareholder value.
Read more →CNTB▼ -7.5%on this news· ran to +22% by day 3shared move
Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference
Connect Biopharma Holdings Limited will participate in the BTIG Virtual Biotechnology Conference on July 29, 2025. The company is focused on developing rademikibart, a next-generation antibody for treating asthma and COPD. This participation highlights their commitment to addressing unmet medical needs in inflammatory diseases.
Read more →CNTB▲ +14.8%on this news· ran to +47% by day 3shared move
Connect Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Connect Biopharma Holdings Limited announced that it has regained compliance with the Nasdaq minimum bid price requirement as of July 15, 2025. The company's American Depositary Shares (ADSs) maintained a closing bid price of at least $1.00 for ten consecutive business days. Consequently, the matter is now resolved, allowing the ADSs to continue being listed and traded on Nasdaq. This compliance milestone supports the company's ongoing clinical development of rademikibart for inflammatory diseases, specifically asthma and COPD.
Read more →CNTBConnect Biopharma's Exclusive Licensee in China, Simcere Pharmaceutical, Announced Submission of its New Drug Application for Rademikibart for the Treatment of Atopic Dermatitis in China
Connect Biopharma's collaborator, Simcere Pharmaceutical, has submitted a New Drug Application for rademikibart to treat atopic dermatitis in China. This monoclonal antibody, designed to target IL-4R, is part of an exclusive collaboration since 2023, with Connect Biopharma remaining eligible for milestone payments. The treatment aims to address a significant market need, as atopic dermatitis affects approximately 70 million individuals in China.
Read more →CNTB▲ +11.8%on this news
Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress
Connect Biopharma presented encouraging clinical data for rademikibart at the EAACI 2025 Annual Congress, demonstrating its efficacy in improving lung function and asthma control in patients with eosinophilic-driven type 2 asthma. The investigational drug significantly reduced the annualized exacerbation rates, particularly in patients exhibiting high eosinophil and FeNO counts. The company plans to continue its Phase 2 studies and expects to report topline data in the first half of 2026.
Read more →CNTBConnect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress
Connect Biopharma Holdings Limited has announced that it will deliver two oral presentations at the EAACI 2025 Annual Congress scheduled from June 13-16, 2025, in Glasgow and virtually. The presentations will focus on Rademikibart, a promising anti-interleukin-4-receptor alpha antibody, and its efficacy in reducing exacerbations and improving lung function in eosinophilic driven, Type 2 asthma. Each presentation will be available on the company's website following the event, showcasing advancements in treatment options for asthma and COPD.
Read more →CNTBConnect Biopharma to Present at Two Upcoming Investor Conferences in June
Connect Biopharma Holdings Limited is set to present at two upcoming investor conferences scheduled for June 4th and June 5th, 2025. The conferences, hosted by Noble Capital Markets and Jefferies, will feature corporate presentations that aim to highlight the company's advancements in asthma and COPD care. Notably, the firm is advancing its product candidate, rademikibart, which has demonstrated strong efficacy and safety in Phase 2 trials. The discussions will provide insight into their clinical strategy and future developments in product trajectories.
Read more →CNTB▲ +8.1%on this news
Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference
Connect Biopharma presented promising data on rademikibart at the ATS 2025 International Conference, highlighting its rapid efficacy and safety in treating asthma and COPD. The clinical trial results showed significant improvements in airway function and reductions in acute exacerbations. Additionally, rademikibart's innovative mechanism of action and enhanced binding affinity to IL-4Rα differentiate it from existing treatments like dupilumab. The company is optimistic about the Phase 2 studies and expects more results in the first half of 2026.
Read more →CNTB▼ -5.6%on this newsshared move
Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update
Connect Biopharma reported its financial results for the first quarter of 2025, highlighting the initiation of Phase 2 studies for rademikibart, a potential treatment for asthma and COPD. The company published positive data from a global Phase 2 study, showing rademikibart's ability to improve lung function significantly. Despite having a strong balance sheet to sustain operations until 2027, Connect Biopharma reported a net loss of $10.3 million during this quarter. The company is preparing for upcoming presentations at the ATS 2025 International Conference.
Read more →CNTBConnect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD
Connect Biopharma has initiated its Phase 2 Seabreeze STAT COPD study to evaluate rademikibart for treating acute exacerbations in COPD patients. The study, which is in cooperation with the FDA, aims to assess the safety and efficacy of rademikibart as an adjunct to standard care. Approximately 160 participants with acute COPD exacerbations will be enrolled globally. The topline data is expected in the first half of 2026, and the results may provide insights into addressing a significant unmet need in COPD treatment.
Read more →CNTBproduct candidates, if approved, by physicians, patients, healthcare payors and others in the medical community. Words such as "aim," "anticipate," "believe," "could," "expect," "feel," "goal," "intend," "may," "optimist
Connect Biopharma has initiated the Phase 2 Seabreeze STAT COPD study to evaluate rademikibart's safety and efficacy for acute exacerbations in COPD. The study aims to enroll about 160 participants and report topline data in the first half of 2026. Rademikibart may represent a significant advancement in treatment, potentially addressing the unmet needs for rapid relief in COPD patients. This initiative follows promising results from earlier studies that suggest strong efficacy for rademikibart in improving patient outcomes during exacerbations.
Read more →CNTB▼ -5.2%on this newsshared move
existing patent terms where available our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for the manufacture of our product candidates for preclinical studies and
Connect Biopharma has launched the Phase 2 Seabreeze STAT Asthma study to evaluate rademikibart for acute exacerbations in asthma patients. This follows positive results from earlier trials, suggesting rademikibart can significantly improve lung function rapidly. The study aims to assess the safety and effectiveness of rademikibart, with topline data expected in the first half of 2026. The company is also preparing to initiate a similar Phase 2 study for chronic obstructive pulmonary disease (COPD).
Read more →CNTB▲ +13.7%on this news
Connect Biopharma Announces Multiple Presentations at the American Thoracic Society (ATS) 2025 International Conference
Connect Biopharma Holdings Limited (Nasdaq: CNTB) will present four posters at the ATS 2025 International Conference, highlighting the clinical development of rademikibart for treating moderate-to-severe asthma and COPD. The presentations will cover various aspects of the drug's efficacy, including its impact on blood eosinophil counts and rapid improvement in lung function. The company plans to initiate parallel Phase 2 trials in Q2 2025 following encouraging results from prior studies. This news reflects ongoing progress by Connect Biopharma in addressing significant unmet needs in respiratory care.
Read more →CNTBConnect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart
Connect Biopharma announced favorable outcomes from its Type C meeting with the FDA concerning rademikibart for treating acute exacerbations in asthma and COPD. The FDA approved the plan to conduct two parallel Phase 2 trials, set to begin enrollment in Q2 2025, targeting patients with moderate-to-severe conditions. The company aims to investigate the effectiveness of a single 600 mg subcutaneous dose over a 28-day span. Results from these trials are anticipated in the first half of 2026, and data from previous studies indicate rademikibart could deliver rapid benefits to patients.
Read more →CNTB▼ -19.1%on this newsshared move
Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma
Connect Biopharma has published positive results from a global Phase 2 trial of rademikibart, highlighting its effectiveness in patients with moderate-to-severe uncontrolled asthma. The trial demonstrated a rapid onset of action and sustained improvements in lung function, evidenced by significant increases in forced expiratory volume (FEV1). Rademikibart also showed a favorable safety profile, with no serious treatment-related adverse events reported. The outcomes suggest rademikibart has the potential to advance into Phase 3 trials for asthma treatment.
Read more →CNTB▼ -19.1%on this newsshared move
Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update
Connect Biopharma has reported its 2024 full-year financial results and offered a business update, highlighting significant leadership changes and strategic advancements. The company is set to initiate Phase 2 trials for rademikibart, targeting acute asthma and COPD exacerbations, with expected data results in late 2026. Despite a strong cash position into 2027, the company reported a net loss of $15.6 million. Connect's efforts to enhance its U.S. presence are evident through management team strengthening and relocation to San Diego.
Read more →CNTB▼ -10.5%on this news· ran to -28% by day 1shared move
Connect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Connect Biopharma Holdings Limited (CNTB) has received a deficiency notice from Nasdaq regarding its failure to maintain the minimum bid price of $1.00 per share for its American Depositary Shares (ADSs) for the past 30 consecutive business days. The company has a 180-day period to achieve compliance, failing which it may face delisting. While there are options for extending compliance, Connect Biopharma must closely monitor its ADS pricing to ensure continued listing on the Nasdaq Global Market.
Read more →CNTBConnect Biopharma to Present at Two Upcoming Investor Conferences
Connect Biopharma Holdings Limited (CNTB) announced its participation in two upcoming investor conferences, including the Leerink Partners Global Biopharma Conference and the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference. The focus will be on their lead candidate, Rademikibart, which is being developed for asthma and COPD. The company is optimistic about the product's potential impact on the market, as evidenced by promising Phase 2 study results.
Read more →CNTBConnect Biopharma to Participate in the Cantor Fitzgerald Global Healthcare Conference 2024
Connect Biopharma Holdings Limited will participate in the Cantor Fitzgerald Global Healthcare Conference 2024, scheduled from September 17th to 19th in New York. The company's management team will present on September 19 at 9:10 a.m. ET and will also host one-on-one meetings with interested investors. Connect Biopharma focuses on developing therapies for inflammatory diseases, with its lead product candidate targeting IL-4 receptor alpha for conditions like atopic dermatitis and asthma.
Read more →CNTB▼ -7.8%on this newsshared move
Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update
Connect Biopharma Holdings Limited reported its financial results for the first half of 2024, highlighting a positive turnaround as the company transitioned to more U.S.-centric operations. Leadership changes have been made with the appointment of Barry Quart as CEO and David Szekeres as President. The company reported an increase in net income and continues to draw on significant cash reserves that are expected to last until at least 2027. Additionally, the company received positive feedback from the FDA regarding the potential for Phase 3 trials of rademikibart in asthma and atopic dermatitis.
Read more →CNTB▼ -5.3%on this news
Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum
Connect Biopharma Holdings Limited (Nasdaq: CNTB) will host one-on-one investor meetings at the Leerink Partners Inflammation and Immunology and Metabolism Therapeutics Forum on July 9-10, 2024, in Boston, MA. The company is focused on developing therapies for chronic inflammatory diseases through T cell-driven research. Their lead product candidates include rademikibart for atopic dermatitis and asthma, and icanbelimod for ulcerative colitis. This engagement presents an opportunity to showcase their pipeline and attract potential investors.
Read more →CNTBConnect Biopharma Announces New Leadership and Chair of the Board of Directors
Connect Biopharma has announced new leadership appointments, naming Barry Quart as Chief Executive Officer, David Szekeres as President, and Kleanthis G. Xanthopoulos as Chair of the Board. These appointments come as the company transitions into a late-stage biopharmaceutical entity with its lead product candidate, rademikibart, poised for commercialization. Outgoing CEO Zheng Wei will stay on the Board as an advisor. The company’s solid financial foundation and experienced management team are anticipated to drive forward its pipeline of therapies for chronic inflammatory diseases.
Read more →CNTBConnect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Connect Biopharma has announced the granting of stock options to its new CEO, Barry Quart, and new President, David Szekeres, as part of an inducement plan compliant with Nasdaq guidelines. The stock options, totaling over 4.4 million shares, will vest over four years, encouraging continued employment. This strategic move comes as the company continues to develop therapies for chronic inflammatory diseases, including its lead product candidate for atopic dermatitis and asthma. It reflects a commitment to attracting leadership talent to advance its clinical-stage biopharmaceutical endeavors.
Read more →CNTB▼ -5.1%on this news
Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma
Connect Biopharma presented positive results from its global Phase 2b trial of rademikibart at the ATS 2024 International Conference. The treatment demonstrated significant improvements in lung function and asthma control in patients with moderate-to-severe asthma. Notably, positive effects were noticeable by Week 1 and sustained for 24 weeks. The company is set for an End-of-Phase 2 meeting with the FDA in Q2 2024 to discuss the next steps in its regulatory path.
Read more →CNTBConnect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma
Connect Biopharma has announced that data from its global Phase 2b trial of rademikibart in moderate-to-severe asthma patients will be presented as a late-breaking abstract at the ATS 2024 International Conference. The poster session is scheduled for May 22, 2024, and will focus on improved lung function and asthma control observed in trial patients. The conference is an important event for the company, showcasing its efforts in developing treatments for chronic inflammatory diseases.
Read more →CNTBConnect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
Connect Biopharma announced positive financial results for 2023, highlighted by two successful trial readouts for rademikibart in asthma and atopic dermatitis. The company is set to engage with the FDA in Q2 2024 to discuss pathways for U.S. approval. Additionally, Connect has secured a partnership with Simcere for the development of rademikibart in Greater China. The company's financial outlook remains strong, with sufficient cash reserves to sustain operations into 2026.
Read more →CNTB▼ -8.9%on this news
Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors
Connect Biopharma has appointed James Huang to its Board of Directors, effective immediately. Huang brings over 30 years of biotech experience and is a significant shareholder through his firm, Panacea Venture. His expertise is expected to contribute valuable insights as the company advances its pipeline of therapies for chronic inflammatory diseases. This appointment follows positive developments in the company's lead product, rademikibart, targeting atopic dermatitis and asthma.
Read more →CNTB▼ -9.1%on this news· ran to -22% by day 1
Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma • The global trial met its primary endpoint showing both doses of radem
Connect Biopharma announced positive topline results from a global Phase 2b trial of rademikibart in adult patients with moderate-to-severe persistent asthma. The trial met its primary endpoint, demonstrating significant improvements in lung function at Week 12 that persisted through Week 24. Early improvements in asthma control were sustained for both dosing regimens. Safety data indicated that rademikibart was generally well tolerated, with no new safety signals noted.
Read more →CNTBConnect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023
Connect Biopharma Holdings Limited will announce top-line data from its global Phase 2b trial of rademikibart, targeting moderate-to-severe asthma, on December 12, 2023. This presentation will occur prior to the market opening, followed by a conference call featuring Dr. Edward M. Kerwin, MD. The results from this trial are critical for assessing rademikibart's efficacy and safety in patients with this condition. The company's ongoing focus is on developing innovative therapies for chronic inflammatory diseases.
Read more →CNTB▼ -38.8%on this news
Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China
Connect Biopharma has entered into an exclusive licensing and collaboration agreement with Simcere Pharmaceutical to develop rademikibart for all indications in Greater China. Connect Biopharma retains rights to the treatment in other markets. This partnership bolsters the commercialization efforts of rademikibart following positive results from its pivotal trial for atopic dermatitis in China. Financially, Connect Biopharma will receive an upfront payment and potential milestone payments, positioning the company strongly in the market.
Read more →CNTB▼ -38.8%on this news
EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT by and between Connect Biopharma HongKong Limited and Simcere Pharmaceutical Co., Ltd. Table of Contents 1. DEFINITIONS 3 2. LICENSE 12 3. GOVERNANCE 15 4. DEVELOPMENT AND RE
Connect Biopharma HongKong Limited has entered into an exclusive license and collaboration agreement with Simcere Pharmaceutical Co., Ltd. This agreement defines the governance, development, regulatory matters, and commercialization strategies for the licensed compound. Both parties will work together, leveraging their respective rights and expertise in the field, aiming to enhance drug development and market entry. The agreement covers critical aspects such as intellectual property and compliance with applicable laws.
Read more →CNTB▼ -38.8%on this news
Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis
Connect Biopharma announced positive long-term data from its pivotal trial of rademikibart for moderate-to-severe atopic dermatitis, with efficacy maintained through Week 52. The trial showed that both every two weeks and every four weeks dosing regimens resulted in high percentages of patients achieving IGA 0/1 and EASI-75 response rates. Furthermore, the company is collaborating with Simcere Pharmaceutical to advance the drug's development in Greater China. The results contribute to the understanding of rademikibart's potential as a convenient treatment option for patients.
Read more →CNTBConnect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023
Connect Biopharma Holdings Limited (Nasdaq: CNTB) will announce topline results from the Stage 2 maintenance period of its pivotal trial for rademikibart, addressing efficacy and safety in patients with moderate-to-severe atopic dermatitis. The announcement is scheduled for November 21, 2023, prior to market opening, with an accompanying conference call and webcast presentation at 8:30 a.m. ET. Rademikibart targets the interleukin-4 receptor alpha and represents a key product candidate in the company's pipeline focused on chronic inflammatory diseases.
Read more →CNTBConnect Biopharma Reports First Half 2023 Financial Results and Provides Business Update • Key data readouts with Company's lead drug candidate rademikibart expected in the fourth quarter of 2023 o Topline results
Connect Biopharma reported its financial results for the first half of 2023, highlighting significant advancements in its lead drug candidate rademikibart, with key data readouts anticipated in the fourth quarter. The company reported a cash balance of $131.6 million, sufficient to fund operations into at least 2026 while maintaining progress in multiple clinical trials, including icanbelimod for ulcerative colitis. Despite increased net losses, the company remains focused on its pipeline developments and upcoming milestones.
Read more →CNTBConnect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
Connect Biopharma has received a deficiency notice from Nasdaq regarding its American Depositary Shares, which have been trading below the $1.00 minimum bid price for 30 consecutive business days. The company has until March 11, 2024, to bring the share price back above this threshold to maintain its listing. If the issue is not rectified, there exists an option for an additional compliance period, contingent upon transferring to the Nasdaq Capital Market. The company plans to monitor and take necessary actions during the compliance period.
Read more →CNTBConnect Biopharma to Participate in Upcoming September Investor Conferences
Connect Biopharma Holdings Limited (CNTB) announced its management team's participation in upcoming investor conferences, including the H.C. Wainwright 25th Annual Global Investment Conference on September 11, 2023, and the Cantor Fitzgerald Global Healthcare Conference from September 26-28, 2023. These conferences will allow the team to engage with investors through both presentations and one-on-one meetings. Connect Biopharma is focused on developing therapies for chronic inflammatory diseases through its proprietary drug pipeline. The company aims to improve patient outcomes while advancing its research in T cell-driven therapies.
Read more →CNTBConnect Biopharma Presented Additional Data from its Atopic Dermatitis Pivotal Trial in China at the 2023 World Congress of Dermatology
Connect Biopharma presented new data at the 2023 World Congress of Dermatology from its pivotal trial of rademikibart for moderate-to-severe atopic dermatitis in China. The data indicated that rademikibart met all primary and secondary endpoints, showcasing significant efficacy and safety over a 16-week period. Both investigator-rated outcomes and patient-reported outcomes demonstrated substantial improvements. The company anticipates additional results from the 36-week maintenance phase by the end of 2023.
Read more →CNTBConnect Biopharma to Participate in the SVB Securities Therapeutics Forum
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, announced its participation in the SVB Securities Therapeutics Forum, scheduled for July 11-12, 2023, in New York. The company, which focuses on therapies for chronic inflammatory diseases, aims to engage investors through one-on-one meetings. Its portfolio includes promising product candidates like CBP-201 for atopic dermatitis and asthma, as well as treatments for ulcerative colitis and pruritus.
Read more →CNTBHouse Lease Contract Lessor: Taicang Science and Technology Venture Park Co., Ltd. (hereinafter referred to as “Party A”) Lessee: Suzhou Connect Biopharmaceuticals, Ltd. (hereinafter referred to as “
Suzhou Connect Biopharmaceuticals has entered into a lease agreement with Taicang Science and Technology Venture Park Co., Ltd. for office space located in Taicang City, with the lease term running from May 1, 2023, to April 30, 2026. The total area leased is 2366.81 m2, with specified rent and management fees. The agreement outlines the terms for payment, renewal, and other obligations of both parties, providing various additional supportive services aimed at facilitating business operations. The contract also stipulates conditions for security deposits and implications for breach of terms on either side.
Read more →CNTB▼ -9%on this news
Corporate Presentation June 2023 | NASDAQ: CNTB Developing next-generation therapeutics for T cell-driven inflammatory diseases Forward-looking statements This presentation regarding Connect Biopharma Holdings Limited (
Connect Biopharma Holdings Limited presented its corporate update for June 2023, focusing on its development of next-generation therapeutics for T cell-mediated inflammatory diseases. The company highlighted its pipeline, which includes drugs like CBP-201 and Icanbelimod, designed to address significant unmet needs in the market. While the firm has a solid cash position and potential for innovative therapies, it also acknowledged various risks, including the uncertainties surrounding regulatory approvals and the impact of COVID-19 on clinical trials. This corporate presentation aims to inform stakeholders about the company's strategic directions and future operations.
Read more →CNTBConnect Biopharma Announces Positive Long-Term Data from the Maintenance Period Through Week 48 of CN002 Phase 2 Icanbelimod Trial in Patients with Moderate-to-Severe Ulcerative Colitis • Icanbelimod demonstrated
Connect Biopharma has announced positive results from the Week 48 data of the Phase 2 CN002 trial for Icanbelimod, showing 80% of patients achieved sustained clinical remission after initial treatment. The drug was well-tolerated with no new safety signals, aligning with previous safety data from the induction phase. Overall, 67% of patients who completed the maintenance phase achieved clinical remission. The company is exploring strategic partnerships to advance Icanbelimod into registrational programs.
Read more →CNTB▲ +5.6%on this news
Connect Biopharma Reports Full Year 2022 Financial Results and Provides Business Update CDE's Pre-NDA Feedback Confirms CBP-201 for Atopic Dermatitis on Track for NDA Submission in China by End of First Quarter 2024 SAN
Connect Biopharma reported its full year 2022 financial results, highlighting progress in its clinical development programs, particularly CBP-201 for atopic dermatitis. Based on positive feedback from the Center for Drug Evaluation (CDE) in China, the company plans to submit a New Drug Application by the end of Q1 2024, aiming for potential regulatory approval in 2025. The company also presented recent positive data at a dermatology conference and is progressing trials for other inflammatory diseases. Despite a net loss in 2022, the company remains optimistic about its financial position and future milestones.
Read more →CNTB▼ -10.6%on this news· ran to -27% by day 3
View source version on businesswire.com : https://www.businesswire.com/news/home/20230317005070/en / INVESTOR CONTACT : Ina McGuinness 805.427.1372 imcguinness@connectpharm.com MEDIA CONTACT: Deanne Eagle 917.837.5866 De
Connect Biopharma recently announced positive results from their Phase 2b trial of CBP-201 for moderate-to-severe atopic dermatitis. The post hoc data analysis revealed significant improvements across multiple body regions at both 2-week and 4-week dosing intervals. The findings were presented at the American Academy of Dermatology Annual Meeting, indicating promising potential for CBP-201 as a viable treatment option for patients. Researchers noted the treatment's effectiveness in difficult areas such as the head and neck, contributing to improved quality of life for patients.
Read more →CNTBConnect Biopharma Reports CBP-201 Global Phase 2 Asthma Trial Achieves Full Enrollment SAN DIEGO and TAICANG, SUZHOU, China –
Connect Biopharma has announced the completion of full enrollment for its CBP-201 Phase 2 global trial, which targets moderate-to-severe asthma with Type 2 inflammation. This multicenter, randomized, double-blind study aims to evaluate the efficacy and safety of CBP-201 compared to a placebo. Primary outcomes will focus on lung function, specifically changes in forced expiratory volume (FEV1) at 12 weeks. The company remains optimistic about the candidate's potential effectiveness in treating asthma and other inflammatory diseases.
Read more →CNTBConnect Biopharma to Present at SVB Securities Global Biopharma Conference and Participate in BioCom California
Connect Biopharma Holdings Limited will present at the SVB Securities Global Biopharma Conference on February 15, 2023, and participate in the BioCom Global Partnering and Investor Conference from February 28 to March 2, 2023. The company focuses on developing T cell-driven therapies for inflammatory diseases, with product candidates like CBP-201 for atopic dermatitis and CBP-307 for ulcerative colitis. These presentations highlight their commitment to advancing their innovative drug pipeline.
Read more →CNTB▲ +11.1%on this news
Connect Biopharma Provides Business and Clinical Development Program Update Cash runway now expected to extend into at least 2025 as a result of revised timeline of global Phase 3 program of CBP-201 in atopic dermatitis
Connect Biopharma Provides Business and Clinical Development Program Update Cash runway now expected to extend into at least 2025 as a result of revised timeline of global Phase 3 program of CBP-201 in atopic dermatitis (AD); Longer cash runway permits continued evaluation of
Read more →CNTBConnect Biopharma to Present at the San Francisco Biotech Showcase in January
SAN DIEGO and TAICANG, SUZHOU, China, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today
Read more →CNTBConnect Biopharma To Present at Upcoming Investor and Scientific Conferences
SAN DIEGO and TAICANG, SUZHOU, China, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced it will be presenting an
Read more →CNTB▼ -15.3%on this news
Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China
All primary and key secondary endpoints were met and highly significant at Week 16 in 255 adult patients with moderate-to-severe AD Safety and tolerability results for CBP-201 consistent with targeting the IL-4Rα pathway Data support advancing the regulatory discussions with th
Read more →CNTBConnect Biopharma to Host a Conference Call Tuesday, October 4 to Discuss Topline Results for the Pivotal Trial in China of Lead Candidate, CBP-201, in Patients with Moderate-to-Severe Atopic Dermatitis
Conference call and webcast to take place at 5:30 a.m. PDT/8:30 a.m. EDT, tomorrow, Tuesday, October 4 SAN DIEGO and TAICANG, SUZHOU, China, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a company develop
Read more →CNTBConnect Biopharma Reports First Half 2022 Financial Results and Provides Business Update – Company expects to report top-line data from China pivotal trial for lead drug candidate CBP-201 in atopic dermatitis in O
Connect Biopharma Reports First Half 2022 Financial Results and Provides Business Update Company expects to report top-line data from China pivotal trial for lead drug candidate CBP-201 in atopic dermatitis in October 2022 Company to Host Conference Call Today at 4:30 p.m. ET
Read more →CNTBConnect Biopharma to Report First Half 2022 Financial Results on September 13
Conference call and webcast to follow at 1:30 p.m. PDT/4:30 p.m. EDT SAN DIEGO and TAICANG, SUZHOU, China, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a company developing therapeutics for T cell-driven
Read more →CNTBConnect BioPharma Successfully Completes CBP-174 Phase 1 Single Ascending Dose Study
– CBP-174 in development for pruritus associated with allergic and inflammatory skin diseases, including atopic dermatitis, was observed to be safe and well-tolerated – SAN DIEGO and TAICANG, SUZHOU, China, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Na
Read more →CNTBConnect Moves Forward CBP-201 Top-Line Results Timeline for Pivotal China Atopic Dermatitis Trial to Second Half 2022
— Connect to Evaluate Efficacy and Safety Data on 255 Patients Already Enrolled — — Expected Timing for Potential NDA Approval in China Remains Unchanged and is Targeted for 2025 — SAN DIEGO and TAICANG, SUZHOU, China, July 11, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holding
Read more →CNTB▼ -5.7%on this news· ran to -18% by day 3
Forward-Looking Statements This presentation regarding Connect Biopharma Holdings Limited ("Connect," "we," "us" or "our") has been prepared solely for informational purposes. Certain information contained in this presen
Jefferies Conference Presentation - June 10, 2022 NASDAQ: CNTB DEVELOPING NEXT- GENERATION THERAPEUTICS FOR T CELL DRIVEN INFLAMMATORY DISEASES Exhibit 99.1 Forward-Looking Statements This presentation regarding Connect Biopharma Holdings Limited ("Connect," "we," "us" or "our
Read more →CNTBConnect Biopharma to Participate at the Jefferies Healthcare Conference
SAN DIEGO, CA and TAICANG, SUZHOU, China, June 02, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflam
Read more →CNTBConnect Biopharma Presents CBP-201 Target Engagement and Immune Modulation Data at the Society for Investigative Dermatology Annual Conference
SAN DIEGO, CA and TAICANG, China, May 17, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory di
Read more →CNTBConnect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis Primary endpoint of change from baseline on adapted Mayo Score
Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis SAN DIEGO, CA and TAICANG, China May 3, 2022 Connect Biopharma Holdings Limited (Nasdaq: CNTB) ( Connect Biopharma or the Company ), a global clinical
Read more →CNTBConnect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis
Primary endpoint of change from baseline on adapted Mayo Score for CBP-307 0.2 mg once-daily, orally administered dose showed a numerical improvement, but did not achieve statistical significance Clinical Remission on adapted Mayo Score and other secondary endpoints achieved sta
Read more →CNTBConnect Biopharma Reports Full Year 2021 Financial Results and Provides Business Update - Global Phase 3 Trial of CBP-201 in Moderate-to-Severe Atopic Dermatitis Expected to Commence in H2 2022 - -
Connect Biopharma Reports Full Year 2021 Financial Results and Provides Business Update - Global Phase 3 Trial of CBP-201 in Moderate-to-Severe Atopic Dermatitis Expected to Commence in H2 2022 - - Topline Phase 2 CBP-307 Results in Moderate-to-Severe Ulcerative Colitis (UC)
Read more →CNTBConnect Biopharma Reports Full Year 2021 Financial Results and Provides Business Update
- Global Phase 3 Trial of CBP-201 in Moderate-to-Severe Atopic Dermatitis Expected to Commence in H2 2022 - - Topline Phase 2 CBP-307 Results in Moderate-to-Severe Ulcerative Colitis Expected to Be Reported in H1 2022 - - Cash Balance of RMB 1,706.9 million (USD 267.7 million)
Read more →CNTB▲ +5.1%on this news
Connect Biopharma Appoints Autoimmune and Immunology Expert Chin Lee, MD, MPH as Chief Medical Officer
CMO appointment to propel Connect through clinical milestones across solid pipeline of inflammatory disease therapies in development SAN DIEGOand TAICANG, China, March 01, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma," “Connect,
Read more →CNTBConnect Biopharma to Participate at the SVB Leerink 11th Annual Global Healthcare Conference
SAN DIEGO and TAICANG, China, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory disea
Read more →CNTB▼ -6.3%on this news
Connect Biopharma Presents Data and Analyses from the Global Phase 2b Trial of CBP-201 at the Maui Derm Conference
—Data provides detailed results, with achievement of both primary and key secondary end points and demonstrating significant improvements in skin clearance, disease severity, and itch compared to placebo —Analyses demonstrate that the benefits of CBP-201 to patients continue to
Read more →CNTB▼ -12.3%on this news
Connect Biopharma Reports Detailed Positive Dataset from the Global Phase 2b Trial of CBP-201 in Adult Patients with Moderate-to-Severe Atopic Dermatitis Phase 2b trial previously reported achievement of both primary and
Connect Biopharma Reports Detailed Positive Dataset from the Global Phase 2b Trial of CBP-201 in Adult Patients with Moderate-to-Severe Atopic Dermatitis Phase 2b trial previously reported achievement of both primary and key secondary end points, demonstrating significant impro
Read more →CNTBConnect Biopharma to Host Conference Call on January 5 at 8:30 AM ET to Review Detailed Data from the Global Phase 2b Trial of CBP-201
SAN DIEGO and TAICANG, China, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory disea
Read more →CNTB▼ -8.4%on this news
Connect Biopharma Expands Executive Leadership Team with Hire of Chief Financial Officer
SAN DIEGO, CA and TAICANG, SUZHOU, China, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflam
Read more →CNTB▼ -57.7%on this newsshared move
Connect Biopharma Completes Enrollment of CBP-307 Global Phase 2 Clinical Trial in Moderate-to-Severe Ulcerative Colitis SAN DIEGO, CA and TAICANG
Connect Biopharma Completes Enrollment of CBP-307 Global Phase 2 Clinical Trial in Moderate-to-Severe Ulcerative Colitis SAN DIEGO, CA and TAICANG, SUZHOU, China, Nov. 19, 2021 Connect Biopharma Holdings Limited (Nasdaq: CNTB) ( Connect Biopharma or the Company ), a global clin
Read more →CNTBConnect Biopharma Reports Positive Top-Line Results from the Global Phase 2 Clinical Trial of CBP-201 in Patients with Moderate-to-Severe Atopic Dermatitis Primary endpoint met with all three CBP-201 arms achieving signi
Connect Biopharma Reports Positive Top-Line Results from the Global Phase 2 Clinical Trial of CBP-201 in Patients with Moderate-to-Severe Atopic Dermatitis Primary endpoint met with all three CBP-201 arms achieving significant improvements Significant improvements also reported
Read more →CNTBConnect Biopharma to Participate at Upcoming Conferences
SAN DIEGO, CA and TAICANG, SUZHOU, China, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflam
Read more →CNTB▲ +7.7%on this news
Connect Biopharma to Participate at the Jefferies Virtual China Biotech Summit
SAN DIEGO, CA and TAICANG, SUZHOU, China, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflam
Read more →CNTBConnect Biopharma Announces First Subject Dosed in Phase 2 Trial Evaluating CBP-201 in Adult Patients with Chronic Rhinosinusitis with Nasal Polyps SAN DIEGO, CA and TAICANG, SUZHOU, China September 8 th 2021 Connect Bio
Connect Biopharma Announces First Subject Dosed in Phase 2 Trial Evaluating CBP-201 in Adult Patients with Chronic Rhinosinusitis with Nasal Polyps SAN DIEGO, CA and TAICANG, SUZHOU, China September 8th 2021 Connect Biopharma Holdings Limited (Nasdaq: CNTB) ( Connect Biopharma
Read more →CNTBConnect Biopharma Announces First Patient Dosed in China Pivotal Trial Evaluating CBP-201 in Adults with Moderate-to-Severe Atopic Dermatitis SAN DIEGO, CA and TAICANG, SUZHOU, China September 2 nd 2021 Connect Biopharma
Connect Biopharma Announces First Patient Dosed in China Pivotal Trial Evaluating CBP-201 in Adults with Moderate-to-Severe Atopic Dermatitis SAN DIEGO, CA and TAICANG, SUZHOU, China September 2nd 2021 Connect Biopharma Holdings Limited (Nasdaq: CNTB) ( Connect Biopharma or t
Read more →CNTB▲ +13.7%on this newsshared move
Connect Biopharma Provides Business Update and Reports First Half 2021 Financial Results
- On Track to Report CBP-201 Phase 2B Top-Line Data Evaluating Moderate-to-Severe Atopic Dermatitis (AD) in Q4 of 2021 - - Cash Balance of RMB 2,025.0 Million (USD 313.5 Million) at June 30, 2021 - SAN DIEGO, CA and TAICANG, SUZHOU, China, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Conn
Read more →CNTB▲ +13.7%on this newsshared move
CONNECT BIOPHARMA HOLDINGS LIMITED INDEX TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Page Unaudited Interim Condensed Consolidated Statements of Loss for the six months ended
CONNECT BIOPHARMA HOLDINGS LIMITED INDEX TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Page Unaudited Interim Condensed Consolidated Statements of Loss for the six months ended June 30, 2020 and 2021 2 Unaudited Interim Condensed Consolidated Statem
Read more →CNTB▼ -8.3%on this news
Connect Biopharma to Host First Half 2021 Financial Results Conference Call on September 1, 2021
SAN DIEGO and TAICANG, SUZHOU, China, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammato
Read more →CNTBConnect Biopharma Hires General Counsel & Chief Compliance Officer and Appoints a New Board Member
TAICANG, SUZHOU, China and SAN DIEGO, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammato
Read more →CNTBConnect Biopharma to Participate at the Jefferies Virtual Healthcare Conference
SAN DIEGO and TAICANG, SUZHOU, China, May 26, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammator
Read more →CNTBConnect Biopharma Announces First Subject Dosed in Phase I Trial Evaluating Safety, Tolerability and Pharmacokinetic Profile of CBP-174 in Healthy Adult Subjects Development program exploring the potential of CBP-174 in
Connect Biopharma Announces First Subject Dosed in Phase I Trial Evaluating Safety, Tolerability and Pharmacokinetic Profile of CBP-174 in Healthy Adult Subjects Development program exploring the potential of CBP-174 in the treatment of chronic inflammatory pruritus SAN DIEGO
Read more →CNTBConnect Biopharma Announces First Patient Dosed in Phase 2 Trial Evaluating CBP-201 in Adults with Moderate-to-Severe Persistent Asthma SAN DIEGO and
Connect Biopharma Announces First Patient Dosed in Phase 2 Trial Evaluating CBP-201 in Adults with Moderate-to-Severe Persistent Asthma SAN DIEGO and TAICANG, China, May 12, 2021 (GLOBE NEWSWIRE) Connect Biopharma Holdings Limited (Nasdaq: CNTB) ( Connect Biopharma or the Co
Read more →CNTBConnect Biopharma Completes Enrollment of CBP-201 Global Phase 2 Clinical Trial in Moderate-to-Severe Atopic Dermatitis
SAN DIEGO and TAICANG, China, April 08, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory dise
Read more →CNTBConnect Biopharma Holdings Limited Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares
SAN DIEGO and TAICANG, China, March 23, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the develo
Read more →CNTBConnect Biopharma Holdings Limited announces pricing of Initial Public Offering
SAN DIEGO and TAICANG, China, March 18, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therap
Read more →Competitive Position
How CNTB ranks across every disease it competes inCompetitive Position is a premium feature
See how CNTB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial